WuXi Biologics Congratulates Emergency Use Authorization of Sotrovimab for the treatment of COVID-19
WuXi Biologics, just 15 months after announcing a collaboration with Vir Biotechnology, Inc. (“Vir”) (Nasdaq: VIR) to develop antibodies to treat COVID-19, congratulates the Emergency Use Authorization (EUA) of sotrovimab for the treatment of COVID-19.
Sotrovimab co-developed by VIR and GSK is an investigational single-dose monoclonal antibody for the treatment of mild-to-moderate COVID-19 in adults and pediatric patients with positive results of direct SARS-CoV-2 viral testing, and who are at high risk for progression to severe COVID-19, including hospitalization or death. The EUA announcement and the results of the clinical trials were provided via press release on May 26, 2021.
Dr. Chris Chen, CEO of WuXi Biologics, commented, “We are thrilled to hear this great news and to witness this milestone in the fight against the coronavirus pandemic. Achieving FDA Emergency Use Approval for this COVID-19 antibody in such a short time is a remarkable achievement. This is a perfect example how WuXi Biologics enables our partners in fighting against COVID-19. As the CEO, my heartfelt appreciation and gratitude go out to each WuXi Biologics employee who had many sleepless nights in supporting our clients in the fight against this dreadful pandemic. Their drive to achieve excellence in their work, the overwhelming commitment to their projects, and the unprecedented speed to complete programs has won the trust and confidence of our partners.
About WuXi Biologics
WuXi Biologics (stock code: 2269.HK), a Hong Kong-listed company, is a leading global open-access biologics technology platform offering end-to-end solutions to empower organizations to discover, develop, and manufacture biologics from concept to commercial manufacturing. The company’s history and achievements demonstrate its commitment to providing a truly one-stop service offering and strong value proposition to its global clients.
As of March 22, 2021, there were a total of 361 integrated projects, including 190 projects in pre-clinical development stage, 137 projects in early-phase (phase I and II) clinical development, 32 projects in late-phase (phase III) development and 2 projects in commercial manufacturing. With total estimated capacity for biopharmaceutical production planned in China, Ireland, the U.S., Germany, and Singapore around 430,000 liters after 2024, WuXi Biologics will provide its biomanufacturing partners with a robust and premier-quality global supply chain network.
WuXi Biologics views Environmental, Social, and Governance (ESG) as an integral component of its ethos and business strategy and has established an ESG committee led by the CEO to increase the efficiency while advancing commitment to sustainability. For more information about WuXi Biologics, please visit: www.wuxibiologics.com.